Long-term Outcomes Following Multimodal Therapy in Patients with Metastatic Uveal Melanoma: A Case Study - Takeaways - MDSpire

Long-term Outcomes Following Multimodal Therapy in Patients with Metastatic Uveal Melanoma: A Case Study

  • By

  • Francesca Rifaldi

  • Martina Angi

  • Giuseppe Leone

  • Marta De Ponti

  • Marta Vaiani

  • Andrea Spagnoletti

  • Alice Indini

  • Michele Del Vecchio

  • Lorenza Alessia Di Guardo

  • April 24, 2026

  • 0 min

Share

  • 1

    Uveal melanoma (UM) is a rare intraocular cancer with poor outcomes once metastatic, despite advancements in systemic therapies.

  • 2

    Tebentafusp, an ImmTAC targeting gp100, has improved survival in HLA-A*02:01-positive patients, yet durable responses are still uncommon.

  • 3

    A case study of a 39-year-old woman showed durable disease control after combining tebentafusp with stereotactic body radiotherapy.

  • 4

    The combination therapy resulted in a partial response and maintained excellent quality of life for 35 months post-treatment.

  • 5

    Further prospective studies are needed to evaluate the efficacy of combining tebentafusp with local radiotherapy and to identify predictive biomarkers.

Original Source(s)

Long-term Outcomes Following Multimodal Therapy in Patients with Metastatic Uveal Melanoma: A Case Study

  • by Francesca Rifaldi, Martina Angi, Giuseppe Leone, Marta De Ponti, Marta Vaiani, Andrea Spagnoletti, Alice Indini, Michele Del Vecchio, Lorenza Alessia Di Guardo

  • April 24, 2026

Related Content

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report